)
Vera Therapeutics (VERA) investor relations material
Vera Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Commercial launch and market opportunity
TRUTAKNA launched in the U.S. on July 7; 700 Patient Start Forms were reported in the first 17 weeks, with strong early physician interest.
Starts came from community and academic practices, mainly among prevalent patients still showing abnormal lab values on background IgAN therapies, sometimes after TARPEYO.
At 17 weeks, sibeprenlimab had roughly 1,000 Patient Start Forms versus 700 for TRUTAKNA; both launches were growing, with little direct sales-force competition.
U.S. B-cell modulator opportunity in IgAN was estimated closer to $20B than $10B; three marketed players were expected by year-end, while estimated biopsy-proven U.S. IgAN prevalence was 160,000.
Final phase III efficacy analysis was presented at ASN and published in the New England Journal of Medicine; speakers said the data showed the class could reshape IgAN treatment.
Clinical profile and differentiation
Phase III results showed GFR on TRUTAKNA versus decline on placebo; no treated patients reached transplant, dialysis, or death versus seven on placebo.
Atacicept was described as having a placebo-like safety profile, supported by study in thousands of patients over many years; weekly dosing uses a small-volume, at-home auto-injector.
Nephrologists were said to be comfortable with weekly dosing; 82 field reps reportedly had not encountered weekly administration as a prescribing objection.
Payer strategy is to maintain parity access rather than pursue preferred status; branded step-throughs involving FILSPARI and VANRAFIA affect the B-cell class.
Development plans and expansion
European regulators were aligned on the current IgAN dataset, with a European filing planned for Q1 2027; similar progress was reported in Japan.
Monthly dose-range study data were expected in Q4 2026, comparing three monthly doses with weekly dosing; a weekly-to-monthly cohort was expected to read out after Q1 2027.
Dose selection will assess PK, PD, efficacy, and safety; priorities include preserving efficacy and safety with a single auto-injector injection.
PIONEER is studying a broad range of IgA-mediated disease, including advanced disease, vasculitis, pediatric and transplant patients, plus primary membranous nephropathy, FSGS, and minimal change disease.
In membranous nephropathy, week-four data showed lower anti-PLA2R antibody concentrations and reduced proteinuria; a novel development program is under consideration.
- TRUTAKNA launch gains traction as ORIGIN 3 supports a full-approval bid.VERA
Q3 2026 - ORIGIN 3 showed 76% lower kidney-progression risk with TRUTAKNA through week 104.VERA
Study update - TRUTAKNA's phase III data show strong efficacy and safety, driving rapid U.S. launch momentum.VERA
Morgan Stanley 24th Annual Global Healthcare Conference - Trutakna's launch redefines IgA nephropathy care with strong efficacy, safety, and commercial momentum.VERA
12th Annual Cantor Fitzgerald Global Healthcare Conference - TRUTAKNA launched after FDA accelerated approval; Q2 net loss $109.5M, cash $499.2M.VERA
Q2 2026 - Atacicept stabilized kidney function in IgA nephropathy; phase 3 data expected Q2 2025.VERA
7th Annual Evercore ISI HealthCONx Conference - Atakicept shows strong efficacy and safety in IgAN, with launch and pipeline expansion imminent.VERA
Citi Annual Global Healthcare Conference 2025 - Atacicept nears pivotal data and broad expansion, targeting multiple autoimmune diseases.VERA
R&D Day 2024 - Atacicept achieved a 46% proteinuria reduction and strong safety in phase III IgAN trial.VERA
Study Result
)
)
)
)
)
)
)
)